Form 4: Amylyx Pharmaceuticals Co-CEO Sells Shares to Cover Tax Obligations

Amylyx Pharmaceuticals Co-Chief Executive Officer, Justin B. Klee, sold 7,471 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals, sold 7,471 shares of common stock on January 6, 2025.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $4.0425, with individual transactions ranging from $3.99 to $4.09.
• Following the transaction, Klee directly owns 3,176,788 shares of Amylyx Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction for tax purposes, not a significant event that would impact sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across publicly traded companies.
• The sale of 7,471 shares is relatively small compared to the total holdings of 3,176,788 shares, suggesting this is a routine tax-related transaction rather than a significant divestment.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Justin B. Klee, stock sale, insider trading, restricted stock units, tax obligations